The characterization of DNA methylation alterations specifically in immature CD34+CD15− cells and the identification of several candidate genes implicated in CML progenitor survival or proliferation open new avenues for developing combination therapies with epigenetic drugs and TKIs for the treatment of CP‐CML. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.